QUANtification of Cardiovascular Autonomic Neuropathy (CAN) and the effects of anaesthesia on hemodynamics and cerebral perfusion

QUANtification of Cardiovascular Autonomic Neuropathy (CAN) and the effects of anaesthesia on hemodynamics and cerebral perfusion - QUANCAN Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46328

Enrollment

Registered

2016-06-08

Start date

2016-08-30

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic neuropathy as a result of diabetes cardiovascular autonomic neuropathy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Willing and able to give written informed consent, scheduled for elective, non-cardiothoracic surgery under general anesthesia and age 18 years and above

Exclusion criteria

Exclusion criteria: Day case surgery, laparoscopic procedure, DM type 1, Parkinson*s disease, uncontrolled cardiac arrhythmia, Pure autonomic failure (formerly called idiopathic orthostatic hypotension), Multiple system atrophy with autonomic failure (formerly called Shy-Drager syndrome), Addison*s disease and hypopituitarism, pheochromocytoma, peripheral autonomic neuropathy (e.g., amyloid neuropathy, idiopathic autonomic neuropathy), known cardiomyopathy, extreme left ventricle hypertrophy or ejection fraction

Design outcomes

Primary

Measure	Time frame
Between group difference in hemodynamic parameters and cerebral perfusion parameters.	—

Secondary

Measure	Time frame
Determine the relationship between autonomic function tests and clinical outcome during 30-postoperative days (observational). Outcome measures include frequency of all adverse and serious adverse events.	—

Countries

Netherlands

Outcome results